Radioiodine for remnant ablation and therapy of metastatic disease

Nature Reviews Endocrinology

Volumn 7, Issue 10, 2011, Pages 589-595

  Reiners, Christoph ^a   Hänscheid, Heribert ^a   Luster, Markus ^b   Lassmann, Michael ^a   Verburg, Frederik A ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

CANCER STAGING; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DOSIMETRY; HUMAN; HYPOTHYROIDISM; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; REVIEW;

FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOMETRY; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROTROPIN;

EID: 80053137845     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.134     Document Type: Review

References (97)

1. Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
2. Pacini, F. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787-803 (2006). (Pubitemid 43997716)
3. Pacini, F., Castagna, M. G., Brilli, L. & Pentheroudakis, G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v214-v219 (2010).
4. Luster, M. et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941-1959 (2008).
5. Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418-428 (1994). (Pubitemid 24345593)
6. Eskandari, S. et al. Thyroid Na+/I-symporter. Mechanism, stoichiometry, and specificity. J. Biol. Chem. 272, 27230-27238 (1997). (Pubitemid 27452684)
7. Van Nostrand, D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis. 17, 154-161 (2011).
8. Iyer, N. G., Morris, L. G., Tuttle, R. M., Shaha, A. R. & Ganly, I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer doi: 101002/cncr.26070
9. Schlumberger, M. J. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338, 297-306 (1998). (Pubitemid 28065257)
10. Verburg, F. A., de Keizer, B., Lips, C. J., Zelissen, P. M. & de Klerk, J. M. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur. J. Endocrinol. 152, 33-37 (2005). (Pubitemid 40185450)
11. Mazzaferri, E. L. & Kloos, R. T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86, 1447-1463 (2001). (Pubitemid 32374886)
12. Tubiana, M. et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55, 794-804 (1985). (Pubitemid 15173518)
13. Simpson, W. J., Panzarella, T., Carruthers, J. S., Gospodarowicz, M. K. & Sutcliffe, S. B. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int. J. Radiat. Oncol. Biol. Phys. 14, 1063-1075 (1988).
14. Utiger, R. D. Follow-up of patients with thyroid carcinoma. N. Engl. J. Med. 337, 928-930 (1997). (Pubitemid 27408578)
15. Verburg, F. A., Dietlein, M., Lassmann, M., Luster, M. & Reiners, C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 36, 343-346 (2009).
16. Shattuck, T. M., Westra, W. H., Ladenson, P. W. & Arnold, A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352, 2406-2412 (2005). (Pubitemid 40958437)
17. Sherman, S. I., Tielens, E. T., Sostre, S., Wharam, M. D. Jr & Ladenson, P. W. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 629-634 (1994). (Pubitemid 24083303)
18. Tenenbaum, F., Corone, C., Schlumberger, M. & Parmentier, C. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur. J. Cancer 32A, 1262 (1996). (Pubitemid 126783095)
19. Travagli, J. P. et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 2675-2680 (1998). (Pubitemid 28493759)
20. Taylor, T. et al. Outcome after treatment of high-risk papillary and non Hurthle cell follicular thyroid carcinoma. Ann. Intern. Med. 129, 622-627 (1998). (Pubitemid 28480817)
21. Hay, I. D. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2,444 consecutively treated patients. World J. Surg. 26, 879-885 (2002). (Pubitemid 36920280)
22. Sawka, A. M. et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89, 3668-3676 (2004). (Pubitemid 39089119)
23. Pacini, F. et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur. J. Endocrinol. 153, 651-659 (2005). (Pubitemid 41672411)
24. Rosario, P. W. et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid 17, 1225-1228 (2007).
25. Sawka, A. M. et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am. 37, 457-480 (2008). (Pubitemid 351711675)
26. DeGroot, L. J., Kaplan, E. L., Shukla, M. S., Salti, G. & Straus, F. H. Morbidity and mortality in follicular thyroid cancer. J. Clin. Endocrinol. Metab. 80, 2946-2953 (1995).
27. Mazzaferri, E. L. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7, 265-271 (1997). (Pubitemid 27190594)
28. Samaan, N. A. et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1,599 patients. J. Clin. Endocrinol. Metab. 75, 714-720 (1992).
29. Robbins, R. J. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro 2 deoxy D glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91, 498-505 (2006). (Pubitemid 43236915)
30. Demidchik, Y. E. et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann. Surg. 243, 525-532 (2006).
31. Reiners, C., Demidchik, Y. E., Drozd, V. M. & Biko, J. Thyroid cancer in infants and adolescents after Chernobyl. Minerva Endocrinol. 33, 381-395 (2008).
32. Dottorini, M. E., Lomuscio, G., Mazzucchelli, L., Vignati, A. & Colombo, L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J. Nucl. Med. 36, 21-27 (1995).
33. Hay, I. D. et al. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 World J. Surg. 34, 1192-1202 (2010).
34. Biko, J. et al. Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur. J. Nucl. Med. Mol. Imaging 38, 651-655 (2011).
35. Verburg, F. A. et al. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur. J. Nucl. Med. Mol. Imaging 37, 896-903 (2010).
36. Lassmann, M., Reiners, C. & Luster, M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr. Relat Cancer 17, R161-R172 (2010).
37. Verburg, F. A., Mäder, U., Luster, M. & Reiners, C. Primary tumor diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 71, 291-297 (2008).
38. Verburg, F. A., Mäder, U., Luster, M. & Reiners, C. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. Eur. J. Endocrinol. 160, 619-624 (2009).
39. Seidlin, S. M., Marinelli, L. D. & Oshry, E. Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132, 838-847 (1946).
40. Tuttle, R. M. et al. Thyroid carcinoma. J. Natl Compr. Canc. Netw. 8, 1228-1274 (2010).
41. Hackshaw, A. & Mallick, U. Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer. Clin. Med. Res. 7, 1-3 (2009).
42. Mallick, U., Harmer, C. & Hackshaw, A. The HiLo trial: a multicentre randomised trial of high-versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 20, 325-326 (2008). (Pubitemid 351636017)
43. Doi, S. A. & Woodhouse, N. J. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 52, 765-773 (2000). (Pubitemid 30409270)
44. Hackshaw, A., Harmer, C., Mallick, U., Haq, M. & Franklyn, J. A. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J. Clin. Endocrinol. Metab. 92, 28-38 (2007). (Pubitemid 46075005)
45. Doi, S. A., Woodhouse, N. J., Thalib, L. & Onitilo, A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin. Med. Res. 5, 87-90 (2007).
46. Schlumberger, M. et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37, 598-605 (1996). (Pubitemid 126618447)
47. Menzel, C. et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J. Nucl. Med. 37, 1496-1503 (1996). (Pubitemid 26321630)
48. Van Nostrand, D. in Thyroid Cancer: A Comprehensive Guide to Clinical Management 2nd edn (eds Wartofsky, L. & Van Nostrand, D.) 411-425 (Humana Press, Totowa, 2006).
49. Samuel, A. M., Rajashekharrao, B. & Shah, D. H. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J. Nucl. Med. 39, 1531-1536 (1998). (Pubitemid 28459881)
50. Chiesa, C. et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging 53, 546-561 (2009).
51. Hänscheid, H. et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med. 47, 648-654 (2006). (Pubitemid 46768466)
52. Benua, R. S., Cicale, N. R., Sonenberg, M. & Rawson, R. W. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 1962, 171-182 (1962).
53. Maxon, H. R. et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med. 309, 937-941 (1983). (Pubitemid 13008961)
54. Maxon, H. R. III et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J. Nucl. Med. 33, 1132-1136 (1992).
55. Dorn, R. et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J. Nucl. Med. 44, 451-456 (2003). (Pubitemid 39586024)
56. Tuttle, R. M. et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med. 47, 1587-1591 (2006). (Pubitemid 47545022)
57. Kulkarni, K. et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16, 1019-1023 (2006). (Pubitemid 46141304)
58. Hänscheid, H., Lassmann, M., Luster, M., Kloos, R. & Reiners, C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr. Relat. Cancer 16, 1283-1289 (2009).
59. Hänscheid, H. et al. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. Eur. J. Nucl. Med. Mol. Imaging 38, 1296-1302 (2011).
60. Verburg, F. A. et al. The absorbed dose to the blood is a better predictor of ablation success than the administered (131)I activity in thyroid cancer patients. Eur. J. Nucl. Med. Mol. Imaging 38, 673-680 (2011).
61. Van Nostrand, D. et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12, 121-134 (2002). (Pubitemid 34218137)
62. Flux, G. D. et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 37, 270-275 (2010).
63. Sgouros, G. et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3 dimensional internal dosimetry (3D-ID) software. J. Nucl. Med. 45, 1366-1372 (2004). (Pubitemid 47618537)
64. Bolch, W. E., Eckerman, K. F., Sgouros, G. & Thomas, S. R. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J. Nucl. Med. 50, 477-484 (2009).
65. Prideaux, A. R. et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J. Nucl. Med. 48, 1008-1016 (2007). (Pubitemid 46909931)
66. Mazzaferri, E. L. & Massoll, N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr. Relat. Cancer 9, 227-247 (2002). (Pubitemid 36240764)
67. Maxon, H. R. et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin. Nucl. Med. 8, 123-126 (1983). (Pubitemid 13132215)
68. Sawka, A. M. et al. Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. Endocr. Pract. 14, 175-184 (2008).
69. Morsch, E. P., Vanacor, R., Furlanetto, T. W. & Schmid, H. Two weeks of a low-iodine diet are equivalent to 3 weeks for lowering urinary iodine and increasing thyroid radioactive iodine uptake. Thyroid 21, 61-67 (2011).
70. Weintraub, B. D. & Szkudlinski, M. W. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 9, 447-450 (1999). (Pubitemid 29244921)
71. Haugen, B. R. et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. 84, 3877-3885 (1999). (Pubitemid 30644169)
72. Duntas, L. H. & Biondi, B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur. J. Endocrinol. 156, 13-19 (2007). (Pubitemid 46553899)
73. Luster, M., Felbinger, R., Dietlein, M. & Reiners, C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15, 1147-1155 (2005). (Pubitemid 41720721)
74. Dow, K. H., Ferrell, B. R. & Anello, C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7, 613-619 (1997). (Pubitemid 27371801)
75. Chow, S. M. et al. Health-related quality of life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope 116, 2060-2066 (2006).
76. Tagay, S. et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur. J. Endocrinol. 153, 755-763 (2005). (Pubitemid 43020225)
77. Schroeder, P. R. et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 91, 878-884 (2006). (Pubitemid 43357753)
78. Remy, H. et al. 131I effective half-life and dosimetry in thyroid cancer patients. J. Nucl. Med. 49, 1445-1450 (2008).
79. Vaiano, A. et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl. Med. Commun. 28, 215-223 (2007). (Pubitemid 46192957)
80. Luster, M. et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 30, 1371-1377 (2003). (Pubitemid 37247954)
81. Löffler, M., Weckesser, M., Franzius, C., Kies, P. & Schober, O. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 42, 240-243 (2003). (Pubitemid 38101132)
82. Rosário, P. W., Borges, M. A. & Purisch, S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J. Nucl. Med. 49, 1776-1782 (2008).
83. Frigo, A. et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J. Clin. Endocrinol. Metab. 94, 3472-3476 (2009).
84. Chen, A. Y., Jemal, A. & Ward, E. M. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005 Cancer 115, 3801-3807 (2009).
85. Tuttle, R. M., Leboeuf, R. & Shaha, A. R. Medical Management of thyroid cancer: a risk adapted approach. J. Surg. Oncol. 97, 712-716 (2008). (Pubitemid 351812974)
86. Gramza, A. & Schuff, K. G. Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management. Onco. Targets Ther. 1, 87-101 (2009).
87. Pacini, F. et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926-932 (2006). (Pubitemid 43357760)
88. Elisei, R. et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 94, 4171-4179 (2009).
89. Luster, M. et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 85, 3640-3645 (2000).
90. de Keizer, B. et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur. J. Nucl. Med. Mol. Imaging 30, 367-373 (2003). (Pubitemid 36692861)
91. Robbins, R. J., Driedger, A. & Magner, J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16, 1121-1130 (2006). (Pubitemid 44864487)
92. Borget, I. et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur. J. Nucl. Med. Mol. Imaging 35, 1457-1463 (2008).
93. Borget, I. et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur. J. Endocrinol. 156, 531-538 (2007). (Pubitemid 46796519)
94. Mernagh, P. et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur. J. Endocrinol. 155, 405-414 (2006). (Pubitemid 44463946)
95. Zanotti-Fregonara, P. et al. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Minerva Endocrinol. 33, 53-65 (2008).
96. Barbaro, D. et al. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur. J. Nucl. Med. Mol. Imaging 37, 242-249 (2010).
97. Tala Jury, H. P. et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J. Clin. Endocrinol. Metab. 95, 230-237 (2010).